MAP3K7 and metabolic dysfunction-associated steatotic liver disease: This inhibits Rhbdf2-TAK1 signaling and downstream JNK/NF-κB phosphorylation, and thus exerting a protective effect against NAFLD, including attenuating IRS1 phosphorylation-mediated insulin resistance and thereby inhibiting glucose production.